牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 29,956 shares of common stock on 01/24/2024, as per the latest filing. The shares, valued at an aggregate market value of approximately $748,250, were acquired through open market purchases and restricted stock units (RSUs) on various dates ranging from February to June 2020, with payments made in cash or via stock options. Over the past three months, Lurker has sold a total of 25,044 shares, generating gross proceeds of over $541,000. The planned sale follows a pattern of recent transactions by Lurker, indicating a continued adjustment of her investment in the company.
EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 29,956 shares of common stock on 01/24/2024, as per the latest filing. The shares, valued at an aggregate market value of approximately $748,250, were acquired through open market purchases and restricted stock units (RSUs) on various dates ranging from February to June 2020, with payments made in cash or via stock options. Over the past three months, Lurker has sold a total of 25,044 shares, generating gross proceeds of over $541,000. The planned sale follows a pattern of recent transactions by Lurker, indicating a continued adjustment of her investment in the company.
根據最新文件，EyePoint Pharmicals, Inc.董事南希·盧克定於2024年1月24日出售29,956股普通股。這些股票的總市值約爲748,250美元，是在2020年2月至6月的不同日期通過公開市場購買和限制性股票單位（RSU）收購的，以現金或股票期權支付。在過去的三個月中，Lurker共出售了25,044股股票，總收益超過54.1萬美元。計劃中的出售遵循了Lurker最近的交易模式，這表明她將繼續調整對該公司的投資。
根據最新文件，EyePoint Pharmicals, Inc.董事南希·盧克定於2024年1月24日出售29,956股普通股。這些股票的總市值約爲748,250美元，是在2020年2月至6月的不同日期通過公開市場購買和限制性股票單位（RSU）收購的，以現金或股票期權支付。在過去的三個月中，Lurker共出售了25,044股股票，總收益超過54.1萬美元。計劃中的出售遵循了Lurker最近的交易模式，這表明她將繼續調整對該公司的投資。
有用
沒用